- Home
- AXDX vs COEP Comparison
AXDX vs COEP Comparison
Compare AXDX & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXDX
- COEP
- Stock Information
- Founded
- AXDX 1982
- COEP 2017
- Country
- AXDX United States
- COEP United States
- Employees
- AXDX N/A
- COEP N/A
- Industry
- AXDX Biotechnology: Laboratory Analytical Instruments
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AXDX Industrials
- COEP Health Care
- Exchange
- AXDX Nasdaq
- COEP Nasdaq
- Market Cap
- AXDX 27.0M
- COEP 30.5M
- IPO Year
- AXDX 1996
- COEP N/A
- Fundamental
- Price
- AXDX $0.71
- COEP $9.48
- Analyst Decision
- AXDX Hold
- COEP
- Analyst Count
- AXDX 1
- COEP 0
- Target Price
- AXDX $1.00
- COEP N/A
- AVG Volume (30 Days)
- AXDX 49.1K
- COEP 41.9K
- Earning Date
- AXDX 03-21-2025
- COEP 05-09-2025
- Dividend Yield
- AXDX N/A
- COEP N/A
- EPS Growth
- AXDX N/A
- COEP N/A
- EPS
- AXDX N/A
- COEP N/A
- Revenue
- AXDX $11,698,000.00
- COEP N/A
- Revenue This Year
- AXDX $7.25
- COEP N/A
- Revenue Next Year
- AXDX N/A
- COEP N/A
- P/E Ratio
- AXDX N/A
- COEP N/A
- Revenue Growth
- AXDX N/A
- COEP N/A
- 52 Week Low
- AXDX $0.69
- COEP $2.31
- 52 Week High
- AXDX $2.09
- COEP $13.70
- Technical
- Relative Strength Index (RSI)
- AXDX 22.43
- COEP 44.36
- Support Level
- AXDX $0.69
- COEP $9.01
- Resistance Level
- AXDX $1.09
- COEP $9.75
- Average True Range (ATR)
- AXDX 0.11
- COEP 0.89
- MACD
- AXDX -0.04
- COEP -0.07
- Stochastic Oscillator
- AXDX 2.93
- COEP 42.98
About AXDX Accelerate Diagnostics Inc.
Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.